| Literature DB >> 32432103 |
Zexing Yan1, Heyong Yin1, Christoph Brochhausen2, Christian G Pfeifer1, Volker Alt1, Denitsa Docheva1,3.
Abstract
Tendons are dense connective tissues, which are critical for the integrity and function of our musculoskeletal system. During tendon aging and degeneration, tendon stem/progenitor cells (TSPCs) experience profound phenotypic changes with declined cellular functions that can be linked to the known increase in complications during tendon healing process in elderly patients. Tissue engineering is a promising approach for achieving a complete recovery of injured tendons. However, use of autologous cells from aged individuals would require restoring the cellular fitness prior to implantation. In this study, we applied an established cell sheet model for in vitro tenogenesis and compared the sheet formation of TSPC derived from young/healthy (Y-TSPCs) versus aged/degenerative (A-TSPCs) human Achilles tendon biopsies with the purpose to unravel differences in their potential to form self-assembled three-dimensional (3D) tendon organoids. Using our three-step protocol, 4 donors of Y-TSPCs and 9 donors of A-TSPCs were subjected to cell sheet formation and maturation in a period of 5 weeks. The sheets were then cross evaluated by weight and diameter measurements; quantification of cell density, proliferation, senescence and apoptosis; histomorphometry; gene expression of 48 target genes; and collagen type I protein production. The results revealed very obvious and significant phenotype in A-TSPC sheets characterized by being fragile and thin with poor tissue morphology, and significantly lower cell density and proliferation, but significantly higher levels of the senescence-related gene markers and apoptotic cells. Quantitative gene expression analyses at the mRNA and protein levels, also demonstrated abnormal molecular circuits in the A-TSPC sheets. Taken together, we report for the first time that A-TSPCs exhibit profound deficits in forming 3D tendon tissue organoids, thus making the cell sheet model suitable to investigate the molecular mechanisms involved in tendon aging and degeneration, as well as examining novel pharmacologic strategies for rejuvenation of aged cells.Entities:
Keywords: 3D cell sheet model; tendon age-related degeneration; tendon regeneration; tendon stem/progenitor cells; tenogenesis
Year: 2020 PMID: 32432103 PMCID: PMC7214752 DOI: 10.3389/fbioe.2020.00406
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1Cell sheet procedure and gross morphological data. (A) Cartoon depicting the 3-step protocol for cell sheet formation. (B) Representative macroscopy images Y-TSPC and A-TSPC sheets at day 14. (C) Success rate of all donors (upper panel) success rate of each individual donor (lower panel). (D) Comparison of TSPC sheet wet weight at day 1 and 14. (E) Comparison of TSPC sheet diameter at day 1 and 14. Y-TSPC n = 4; A-TSPC n = 9; *p < 0.05, **p < 0.01, and ***p < 0.001.
Genes included in Real Time PCR Ready Custom Designed Plates analyzed in this study.
| Early growth response 1 | EGR-1 | Tendon transcription factor |
| Early growth response 2 | EGR-2 | Tendon transcription factor |
| Eyes absent homolog 1 | EYA1 | Tendon transcription factor |
| Eyes absent homolog 2 | EYA2 | Tendon transcription factor |
| Mohawk homeobox | MKX | Tendon transcription factor |
| Scleraxis homolog A | SCXA | Tendon transcription factor |
| SIX homeobox1 | SIX1 | Tendon transcription factor |
| SIX homeobox2 | SIX2 | Tendon transcription factor |
| Collagen, type I, alpha 1 | COL1A1 | Collagen gene |
| Collagen, type III, alpha 1 | COL3A1 | Collagen gene |
| Collagen, type V, alpha 1 | COL5A1 | Collagen gene |
| Collagen, type VI, alpha 1 | COL6A1 | Collagen gene |
| Collagen, type XII, alpha 1 | COL12A1 | Collagen gene |
| Collagen, type XIV, alpha 1 | COL14A1 | Collagen gene |
| Collagen, type XV, alpha 1 | COL15A1 | Collagen gene |
| Asporin | ASPN | Collagen cross-linker gene |
| Lysyl oxidase | LOX | Collagen cross-linker gene |
| Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 1 | PLOD1, LH1 | Collagen cross-linker gene |
| Biglycan | BGN | Tendon-related matrix gene |
| Decorin | DCN | Tendon-related matrix gene |
| Ephrin type-A receptor 4 | EPHA4 | Tendon-related matrix gene |
| Fibromodulin | FMOD | Tendon-related matrix gene |
| Fibronectin 1 | FN1 | Tendon-related matrix gene |
| Lumican | LUM | Tendon-related matrix gene |
| Proteoglycan 4 | PRG4 | Tendon-related matrix gene |
| Tenascin C | TNC | Tendon-related matrix gene |
| Thrombospondin 2 | THBS2 | Tendon-related matrix gene |
| Thrombospondin 4 | THBS4 | Tendon-related matrix gene |
| Tenomodulin | TNMD | Tendon-related matrix gene |
| Aggrecan | ACAN | Other lineage gene |
| Collagen, type II, alpha 1 | COL2A1 | Other lineage gene |
| Alpha-actin-2 | ACTA2, | Other lineage gene |
| Cartilage oligomeric matrix protein | COMP | Other lineage gene |
| Desmin | DES | Other lineage gene |
| Integrin-binding sialoprotein | IBSP | Other lineage gene |
| Fucosyltransferase 4 | FUT4 | Other lineage gene |
| Lipoprotein lipase | LPL | Other lineage gene |
| Myogenic differentiation 1 | MYOD1 | Other lineage gene |
| Myogenin | MYOG | Other lineage gene |
| Nanog homebox pseudogene 8 | NANOG | Other lineage gene |
| Octamer-binding transcription factor 4 | Oct4, Pou5f1 | Other lineage gene |
| Peroxisome proliferator-activated receptor gamma | PPARG | Other lineage gene |
| Runt-related transcription factor 2 | RUNX2 | Other lineage gene |
| Transcription factor Sp7 | SP7, Osterix | Other lineage gene |
| SRY (sex-determining region Y)-box 9 | SOX9 | Other lineage gene |
| Transcription factor AP-2 alpha | TFAP2A | Other lineage gene |
| Transforming growth factor beta 1 | TGF-β1 | Other lineage gene |
| Transglutaminase 2 | TGM2 | Other lineage gene |
| Beta-2-Microglobulin | B2M | Reference gene |
| Glyceraldehyde 3-phosphate dehydrogenase | GAPDH | Reference gene |
| Hypoxanthine-guanine phosphoribosyltransferase 1 | HPRT1 | Reference gene |
PCR for senescence-related genes p16, p21, p53.
| p16 | F 5′-caacgcaccgaatagttacg-3′ | 57 | 35 | |
| R 5′-agcaccaccagcgtgtc-3′ | ||||
| p21 | F 5′-gaacttcgactttgtcaccgag-3′ | 60 | 30 | |
| R 5′-cgttttcgaccctgagagtctc-3′ | ||||
| p53 | F 5′-aaggaaatttgcgtgtggag-3′ | 58 | 35 | |
| R 5′-ttctgacgcacacctattgc-3′ |
FIGURE 4Representative transmission electron microscopy (TEM) images of Y-TSPC and A-TSPC sheets. (a–c) Y-TSPC sheet cell arrangement, cell density and morphology. (d–f) Close view of Y-TSPC morphology and cell protrusions. (g–i) A-TSPC sheet cell arrangement, cell density and morphology. (j–l) Close view of A-TSPC morphology and cell protrusions. Black arrows, apoptotic cells; green arrows, cell protrusions; red arrows, cell–cell contact; m, mitochondria; n, nucleus; v, vacuoles; *, longitudinal cell; Y-TSPC n = 3, A-TSPC n = 5 were investigated.
FIGURE 5Representative transmission electron microscopy (TEM) images of Y-TSPC and A-TSPC sheets. (a–c) Y-TSPC sheet collagen fibrils. (d) Y-TSPC sheet plasmalemma vesicles at the cell membrane. (e) Y-TSPC sheet cell-to-cell contacts between cells. (f) Y-TSPC sheet close view of apoptotic bodies. (g–i) A-TSPC sheet collagen fibrils. (j) A-TSPC sheet plasmalemma vesicles at the cell membrane. (k) A-TSPC sheet cell-to-cell contacts between cells. (l) A-TSPC sheet close view of apoptotic bodies. Arrow head, collagen fibrils; black arrows, apoptotic cells, brown arrows, plasmalemma vesicles; red arrows, cell–cell contact; m, mitochondria; n, nucleus; v, vacuoles; Y-TSPC n = 3, A-TSPC n = 5 were investigated.
FIGURE 2Y-TSPC and A-TSPC histomorphometrical analyses. (A) Representative H&E images of Y-TSPC and A-TSPC sheets at day 14. (B) Frequency distribution of nuclear angle deviation (left panel) as well as maximum and average values of angular deviation (right panel, virtual angle between cell sheet longitudinal axis and nuclear axis). The arrow indicates the higher frequency of nuclear deviation of 10°–20° deviation in the Y-TSPC sheets. (C) Representative images of nuclear staining via DAPI (blue color) of Y-TPSC and A-TPSC sheets. (D) Average cell density of both groups. (E) Frequency distribution of NAR (nuclear aspect ratio, nucleus width versus length). The arrow indicates the higher tendency of NAR 0.8-1 (round cells) in A-TSPC group. (F) Representative F-actin images of Y-TSPC and A-TSPC sheets at day 14. Y-TSPC n = 4; A-TSPC n = 6; *p < 0.05*.
FIGURE 3Quantitative analyses of cell proliferation, apoptosis and senescence. (A,B) Resazurin assay and DNA quantification at 2D prior sheet collection. (C) DNA quantification at 3D day 1 and day 14. (D) Representative TUNEL/DAPI images at 3D day 14. Apoptotic cells appear in green. Positive control with DNase treated. Negative control with label solution only (without terminal transferase). (E) Quantification of average apoptotic cell number in the sheets at day 14. (F) Quantitative PCR analysis of p16, p21, and p53. Y-TSPC n = 4; A-TSPC n = 6; *p < 0.05 and ***p < 0.001. For PCR, Y-TSPC n = 3; A-TSPC n = 3.
FIGURE 6Quantification of elongated cells (A), collagen fibrils and diameter distribution (B,C) and apoptotic cell numbers (D) from TEM images. Y-TSPC n = 3; A-TSPC n = 5; for (A,B,D), 6 images/donor were analyzed; for (C) 20 randomly chosen fibrils per image were assessed; *p < 0.05.
FIGURE 7Collagen I protein production and gene expression profiling by Real Time PCR. (A) Representative collagen I immunofluorescent images of Y-TSPC and A-TSPC sheets at day 14. (B) Quantitative analysis of collagen I by ELISA. For (A,B) Y-TSPC n = 3; A-TSPC n = 6. Normalization to DNA. Quantitative PCR analysis for tendon-transcription factors (C), collagen genes (D), cross-linker genes (E), tendon-related ECM genes (F) other lineage genes (G). Gene expression was calculated as fold change to Y-TSPC group. GAPDH was used as reference gene in each group. Non-detectable (Ct over 38 genes were not included in the graphs. For (C–G) Y-TSPC n = 3; A-TSPC n = 3; ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.